clinical trial · NCT06116968
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Obstructive Hypertrophic CardiomyopathyAficamten
brief summary
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.
started
Nov 14, 2023
primary completion
Oct 20, 2025
completion
Oct 20, 2025
last updated
Jan 21, 2026
official title
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol